Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

929
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
929
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

56
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

279
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
279
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

328
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
328
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

200
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
200
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

427
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
427

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating social health assessments into routine clinical care.

The American journal of nursing·2026
Same author

Discharge bundles reduce length of stay.

The American journal of nursing·2026
Same author

ICU survivors experience multiple symptoms after discharge.

The American journal of nursing·2026
Same author

Web-based support intervention is beneficial for caregivers of patients with cancer.

The American journal of nursing·2026
Same author

Birth: From obscurity to hot topic.

Anatomical record (Hoboken, N.J. : 2007)·2026
Same author

Suboptimal engagement with home blood pressure monitoring.

The American journal of nursing·2026

Related Experiment Video

Updated: Oct 2, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Statin Use Associated with Diabetes Progression.

Karen Rosenberg

    The American Journal of Nursing
    |February 24, 2022
    PubMed
    Summary

    Statin use may increase the risk of worsening diabetes and related complications. Healthcare providers should balance statin benefits against potential diabetes progression risks in patients with diabetes.

    Area of Science:

    • Cardiovascular Medicine
    • Endocrinology
    • Pharmacology

    Background:

    • Statins are widely prescribed for cardiovascular disease prevention.
    • Diabetes is a growing global health concern with significant morbidity and mortality.

    Purpose of the Study:

    • To investigate the association between statin use and the risk of diabetes treatment escalation and hyperglycemic complications.
    • To inform clinical decision-making regarding statin therapy in diabetic patients.

    Main Methods:

    • A large national cohort study design was employed.
    • Data from a national cohort were analyzed to assess outcomes related to statin use in patients with diabetes.

    Main Results:

    • Statin use was linked to a higher likelihood of escalating diabetes treatment.

    More Related Videos

    An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
    10:17

    An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

    Published on: April 26, 2019

    7.1K
    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
    06:22

    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

    Published on: November 29, 2024

    788

    Related Experiment Videos

    Last Updated: Oct 2, 2025

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
    09:15

    Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

    Published on: November 10, 2017

    14.8K
    An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
    10:17

    An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes

    Published on: April 26, 2019

    7.1K
    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
    06:22

    Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

    Published on: November 29, 2024

    788
  • An increased risk of hyperglycemic complications was observed in patients using statins.

    • Conclusions:

    • The potential for statins to accelerate diabetes progression necessitates careful consideration.
    • Clinical decisions on statin therapy should weigh cardiovascular benefits against diabetes-related risks.